About Dako
Dako is a Healthcare company based in Glostrup (Denmark) founded in 1996, and was acquired by Agilent in May 2012. It operates as a reagents, instruments, software, and consulting for cancer diagnostics are supplied. Dako has completed 1 acquisition, including CytoLogix. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Founded in 1996 in Glostrup, Denmark, Dako operates in the diagnostics sector, with a focus on cancer through tissue-based solutions. Reagents and kits for immunohistochemistry, molecular pathology, flow cytometry, and special stains are offered, alongside instruments, software, and consulting services. Acquisition by EQT occurred in 2007 for DKK 7,250 million, followed by sale to Agilent Technologies in 2012 for 2.2 billion USD.
Investors in Dako
Dako has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Agilent and EQT.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Diversified instruments are developed for scientific and laboratory management. | 1995 | agilent.com | Santa Clara, United States |
Investor details for Dako
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dako
672 people are tracked at Dako (189 in leadership, 10 in board & advisors, 473 in team).
| Name | Role | Group |
|---|---|---|
Adam S. Elinoff | Senior Vice President, Chief Financial Officer | Leadership |
Jamie Andalis | Associate Vice President, Molecular And Biological Research & Cellular Analysis | Leadership |
Bret Dimarco | SVP, Agilent & Chief Legal Officer & Secretary | Leadership |
Yijing Chen | Director, Transformation & Program Management Office, Global Instrument Manufacturing | Leadership |
Rob Freeman | Marketing Director For Small Molecule LC And GPC Columns | Leadership |
Andrew Young | Finance Lead And Ireland Company Director | Leadership |
Tyler Steece | Human Resources Business Partner | Leadership |
Babs Sekel | Associate Vice President | Leadership |
George Gonzalez | Director, Global Segment Marketing Director | Leadership |
Mark Meehan | Director Of Investor Relations | Leadership |
Joydeep Ganguly | Chief Operations And Quality Officer | Leadership |
Steve Siembieda | Product Marketing Director | Leadership |
James Culhane | Director Of Web Publishing/web Operations, Digital Analytics And Strategy | Leadership |
Mary Gibson | Head Of Engineering NASD | Leadership |
David Jury | Associate Director Of Engineering | Leadership |
Pundalik Kudapkar | Director, Software & Technology Standards | Leadership |
Bryan Matsuyoshi | Enterprise Solutions And Customer Success Division, Director Of Solution Deployment And Engineering | Leadership |
Gub Singh | Vice President, EMEA Customer Service Organisation | Leadership |
Roben Owen | Director, HR | Leadership |
Padraig McDonnell | President & CEO | Leadership |
652 more people are available in the full profile.
Complete people profiles for Dako
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dako
Dako has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CytoLogix.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Tissue-staining instruments for cancer diagnosis were developed. | cytologix.com | Cambridge, United States | 1996 | Sep 2002 | •••• |
Complete acquisition details for Dako
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Competitors of Dako
Dako has 9 listed competitors in our database, 9 of them funded. They include Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| billiontoone.com | 2015 | San Francisco, United States | $388.62M | 47 | Provider of cell-free cancer liquid biopsy test |
Detailed competitors of Dako
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dako
The website of Dako (dako.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 22.6% vs previous month
Websites whose visitors overlap most with Dako. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mabtech.com | 100% | 22K | #1,229,768 | View details | |
dialab.dp.ua | dialab.dp.ua | 92% | – | #4,391,429 | – |
| advimmuno.com | 92% | 680.7K | #5,715,766 | View details | |
| pro-lab.com | 87% | – | #3,610,074 | View details | |
| ventana.com | 81% | – | #13,526,773 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Dako
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as Dako (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dako
Dako was founded in 1996.
Dako is headquartered in Glostrup, Denmark.
Founded in 1996 in Glostrup, Denmark, Dako operates in the diagnostics sector, with a focus on cancer through tissue-based solutions. Reagents and kits for immunohistochemistry, molecular pathology, flow cytometry, and special stains are offered, alongside instruments, software, and consulting services. Acquisition by EQT occurred in 2007 for DKK 7,250 million, followed by sale to Agilent Technologies in 2012 for 2.2 billion USD.
Dako's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Dako has made 1 acquisition, including CytoLogix.
Yes. Dako was acquired by Agilent in May 2012.